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Abstract – The symptoms of Alzheimer’s disease reflect a loss of neural circuit integrity in the brain, but 
neurons do not work in isolation.  Emerging evidence suggests that the intricate balance of interactions 
between neurons, astrocytes, microglia, and vascular cells required for healthy brain function becomes 
perturbed during the disease, with early changes likely protecting neural circuits from damage, followed 
later by harmful effects when the balance cannot be restored.  Moving beyond a neuronal focus to 
understand the complex cellular interactions in Alzheimer’s disease and how these change throughout the 
course of the disease, may provide important insight into developing effective therapeutics.  
 
 
[H1] Introduction 
 
Alzheimer’s disease (AD), the most common cause of dementia in the elderly, poses a growing problem for 
society as our population ages 1. The overwhelming evidence that neuronal damage downstream of key 
pathological players causes cognitive decline has led to a “neuro-centric” view of AD pathogenesis.  
However, advances in our understanding of the molecular pathogenesis of AD approached from this 
neuro-centric perspective have thus far failed to translate into effective therapies.  This reflects in part a 
failure to fully consider the effects of primary pathological changes on all cell types involved in neural 
system integrity, and the consequent perturbations of many key intercellular interactions.   
 
In this review, we discuss the evidence supporting a role for interactions of multiple cell types in early AD 
pathogenesis, and how this can inform development of therapeutic strategies.  Both the advances in 
fundamental understanding of disease and the outcomes of clinical trials over the past decade indicate the 
importance of cellular interactions early in the disease process 2.   
 
[H1] Early brain changes in AD 
 
Alzheimer’s disease is pathologically defined by the presence of amyloid beta (A) accumulation in amyloid 
plaques, tau aggregation in neurofibrillary tangles, and brain atrophy caused by loss of neurons and 
synapses (Box 1).   In addition to these definitive pathological lesions, the brain undergoes an innate 
immune response including large changes in the phenotypes of microglia and astrocytes.  A substantial 
amount of evidence supports the amyloid cascade hypothesis of disease pathogenesis, which states that 
alterations in Aß initiate the disease and set off a chain of events including accumulation of toxic forms of 
tau that cause downstream neuron death 3,4.   This is strongly supported both by the genetics of familial AD 
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implicating A production and aggregation in causing disease and by the pathological accumulation of A 
deposits beginning many years before symptom onset.  Along with the changes in A early in disease, 
there is an early loss of synapses which tracks with disease progression.  There are also early changes in 
non-neuronal cell types including an inflammatory response of glia around plaques and disruptions to 
vascular function including reduced cerebral blood flow and blood-brain-barrier disruptions (table 1). 
 
[H2] Risk factors point to multiple cells 
The interest in cellular interactions in AD pathogenesis is increasing as both genetic and epidemiologic 
evidence point to a causative role for changes in the innate immune system, metabolism, and vasculature. 
These have initiated a boom of research in the field to understand the non-neuronal contributors and cell-
cell interactions in initiating changes in the brain in the early stages of disease 2,5-8. Early genetic evidence 
implicated the apolipoprotein E epsilon 4 allele (APOE4) as a potent risk factor for AD 9.  APOE is highly 
expressed in astrocytes and disease-associated microglia in the brain, implicating a role for these cell types 
in pathogenesis.  However, it was not until the more recent genome-wide association (GWAS), whole-
genome and whole-exome sequencing studies implicating multiple AD risk genes expressed predominantly 
in non-neuronal cells, that the interest in non-neuronal contributors to AD has really taken hold (table 2). 
In particular, genetic evidence has directly linked microglial function to AD. Several genes involved in the 
innate immune system and inflammation increase AD risk, including triggering receptor expressed on 
myeloid cells 2 (TREM2), complement receptor 1 (CR1), CD33, and INPP5D.  Astrocytic metabolism gene 
variants, in addition to APOE4, have also been implicated in AD pathogenesis including clusterin (CLU, also 
known as apolipoprotein J) and sortilin-related receptor 1 (SORL1). Interestingly, several genes that are 
highly expressed in oligodenrdocytes or oligodendrocyte precursor cells (OPCs) have also been implicated 
in AD risk, although the role of these cells in the disease is much less studied than that of neurons, 
microglia and astrocytes.  
 
Non-genetic risk factors also point to an important role of interactions of multiple cell types in disease 
pathogenesis. The mantra “what is good for your heart is good for your brain” is central advice for 
dementia prevention based on a large amount of evidence implicating vascular risk factors such as high 
blood pressure, obesity, type 2 diabetes, and a sedentary lifestyle, in substantially increasing AD risk 6.  
More recently, direct interactions of AD pathological proteins with the vasculature, have suggested 
changes in vascular function and stability 10,11.  All of these risk factors implicate non-neuronal cell types 
including vascular cells and glia in disease.  While the mechanisms of neurodegeneration initiated by 
interactions between cell types and the timing of these interactions remains unclear, many recently 
discovered pathways converge on synapse degeneration as will be discussed later. 
 
[H1] Inflammation and the immune response  
The brain’s inflammatory response to toxic stimuli involves multiple cell types and cellular interactions. 
Both microglia and astrocytes respond to toxic stimuli in the brain by altering their gene expression, 
morphology, and secretomes, which have cascading effects on other cell types, including neurons.  The 
dramatic envelopment of amyloid plaques by glial cells, and the evidence supporting inefficient Aß 
clearance as a pathogenic pathway in sporadic AD have driven much of the work surrounding inflammation 
to focus on the role of glia in clearing Aß.  Clearing toxic forms of Aß from the brain should be 
neuroprotective, however, Aß also has effects on glial function, which can render them neurotoxic. 
 
 
[H2] Role of glia in amyloid clearance 
Microglia accumulate around plaques in AD and are well known for their ability to phagocytose Aß. This 
begins at the early stages of disease as plaques accumulate in the neocortex.  Many mouse models of this 
early stage of disease exist, which express familial AD-associated mutations in APP and PS1 and develop 
plaques and associated gliosis in the absence of neurofibrillary tau pathology or overt neuron loss.   In one 
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such model, microglia form a barrier around plaques which prevent accumulation of toxic oligomeric Aß 
“hotspots” 12. However, chronic microglial activation leads to a more damaging proinflammatory state 13.  
For example, activated microglia are thought to recruit and activate other microglia through a self-
perpetuating loop of cytokine release and receptor expression 14.  Ablating CX3CL1-positive microglia in 
plaque-bearing mice results in plaque growth, but no change in number, in support of an important role 
for these cells in limiting plaque expansion 15.  However, this finding is inconsistent as previous work in the 
same APP/PS1 model showed that a 90% pharmacological reduction of CD11b-positive microglia had no 
effect on plaque formation or maintenance 16. Furthermore, ablating CSF1R-positive microglia in 5xfAD 
mice has no effect on amyloid burden, but does improve spine loss, neuron death and cognition 17,18. 
Soluble Aß is thought to be much more neurotoxic than plaque fibrils, and recent evidence also supports a 
role for microglia in clearing soluble Aß by secreting Aß-degrading enzymes in a process regulated by 
complement receptor 3 19.  In contrast to the data showing microglial ablation results in plaque growth, 
other data indicate that blocking proliferation of microglia may be beneficial to cognition in mice 17,18.  
Thus, despite a clear role for microglia in clearing Aß, it is not yet clear whether microglial activation is 
protective or harmful, or more likely, whether this depends on the stage of the disease.  Further, in many 
of the studies examining microglia in AD models discussed here, it has not been possible to distinguish 
between microglia, brain macrophages and infiltrating bone marrow-derived cells.  More detailed 
investigations will be needed to determine whether the effects observed are due to microglia or other 
myeloid cells. 
 
Advances in single-cell profiling technology are starting to unravel some of these microglial mysteries both 
by helping to differentiate the different myeloid cell types and to tease out how these cells change upon 
activation.  Recent data indicate that there are likely not just on/off states but a continuum of glial 
activation 20-23. Single-cell RNA sequencing (RNAseq) in an AD mouse model revealed disease associated 
microglia (or DAMs), which accumulate around plaques and exhibit reduced expression of homeostatic 
genes and increased expression of genes involved in phagocytosis 23. Interestingly, two of the upregulated 
genes in DAMs are genetic risk factors for AD, APOE, and TREM2, providing a link between these molecules 
and microglial activation that may explain some of the risk these polymorphisms confer. More detail on 
the link between TREM2 and APOE recently emerged in a transcriptomic analysis of microglia showing that 
TREM2 can be activated by APOE signalling in disease-associated microglia 24.  Interestingly, TREM2 binds 
to ApoE and clusterin (another genetic risk factor) and facilitates microglial uptake of Aß, which is impaired 
by AD associated variants, at least in cell culture 25.  A more complex disease-stage dependent role of 
TREM2 is becoming evident from in vivo studies.  In one model of AD, TREM2 knockout was found to 
ameliorate amyloid pathology early in disease but exacerbate pathology later in the disease process 26,  
highlighting the variability in effects of microglial phenotypes at different stages of disease. While the data 
are not yet all in agreement, several studies suggest a protective role in which upregulation of TREM2 
causes microglia to phagocytose Aß.  In support of this idea, genetic reduction of TREM2 levels in mice and 
the R47H TREM2 mutation in both mice and humans, reduced microglial or monocyte association with 
plaques 26-30, implying that reductions in TREM2 reduce the “barrier” of microglia around plaques that may 
protect surrounding tissue 31.  Lack of TREM2 appears to reduce the ability of microglia to sense their 
environment and respond appropriately, resulting in reduced phagocytosis 32.  
 
Reactive astrocytes accumulate around plaques and are thought to play a role in Aß degradation, thus 
appearing to act in a neuroprotective manner 33. This effect may be due to the increased expression of 
insulin degrading enzyme (IDE), which is observed in vitro in cultured astrocytes and in vivo in astrocytes 
near amyloid plaques 34. Alternatively, astrocytic matrix metalloproteinases (MMPs) may be involved in 
extracellular Aß breakdown. Numerous MMPs are expressed in astrocytes and their levels increase 
following Aß exposure in vitro 35 and in the brains of AD mice 36. Conversely, astrocytes may contribute to 
peri-plaque pathology by releasing pathological factors such as S100β. This protein is enriched in AD brain 
and levels positively correlate with the number of dystrophic neurites within plaques 37.  APOE is also 
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expressed in astrocytes and is thought to play a role in astrocytic amyloid clearance (as well as initial 
deposition and remodelling of Aß into dense core plaques).  Expressing human APOE isoforms indicates 
that APOE4 exacerbates plaque deposition in mouse models of AD compared to APOE2 or APOE3 38.  In 
contrast, complete ablation of APOE in mice reduces plaque deposition 39,40. These APOE null data remain 
incompletely understood, but may have more to do with amyloid production and seeding in neurons than 
with amyloid clearance by astrocytes.  Aβ also induces Ca2+dysregulation in astrocytes in vitro41,42 and in 
vivo 43 , and astrocytes from human post-mortem AD brain show alterations in expression of genes 
associated with Ca2+ signalling, contributing to impaired astrocyte function. 
 
[H2] Glia and tau pathology  
Tau pathology correlates more strongly with neuron loss and cognitive decline in AD than amyloid 
pathology, and extensive tau pathology throughout the brain is only present at later stages of the disease 
process downstream of initial insults.  However, tau pathology does accumulate in the entorhinal region 
early in the disease and the spread of tau out of the medial temporal lobe is thought to be important for 
moving from the early stages of the disease in which brain circuits compensate well for pathology, to the 
later stages of progressive worsening of symptoms 44.  There is some evidence that non-neuronal cell types 
may play a role in tau induced neuron death and perhaps also in its spread through neural circuits. As well 
as their well-known plaque associations, glia accumulate in the vicinity of neurofibrillary tangles and the 
burden of glia positively correlates with tangle burden in human AD brain 45. Further, gliosis occurs in non-
AD tauopathies and tau pathology can accumulate in astrocytes 46. In support of interactions of glia with 
tau-induced neurodegeneration, transplantation of human neural precursor cells into a mouse model of 
tauopathy resulted in glial cell differentiation that protected mice from neuron loss 47. Both APOE and 
TREM2 have also recently been linked to inflammation in tau models. TREM2 deficiency in a mouse model 
of tauopathy reduced inflammation and prevented neurodegeneration at late stages of disease 46, 
however TREM2 reduction in a different tauopathy model examined at an earlier stage showed an 
exacerbation of tau phosphorylation 48. Furthermore, overexpression of TREM2 in microglia of P301S mice 
(a model of tauopathy), reduced tau phosphorylation and suppressed secretion of pro-inflammatory 
cytokines 49.  These emerging data on TREM2 indicate that it may have different effects on tau pathology 
at different stages of disease (similar to the emerging story with A), or at least that it has different effects 
in different mouse models.  Although the data examining the relationship between TREM2 and tau are still 
sparse, they do urge caution in pursuing therapeutic strategies to activate TREM2 before we fully 
understand the role of this molecule in the disease.   
 
Similarly, most work examining effects of APOE4 on AD have focused on Aβ or synapse loss, but there are 
now hints that APOE may also affect tau pathology, likely through modulating glial function. In a mouse 
model overexpressing frontotemporal dementia associated P301S mutant tau, knocking out APOE 
protected mice from neurodegeneration, while knocking in human APOE exacerbated neurodegeneration 
in an isoform specific manner with APOE4 being most toxic 50.  Further, profiling of gene expression 
showed an increase in pro-inflammatory and a decrease in homeostatic gene expression in microglia and 
an increase in inflammatory profiles in astrocytes 50. It remains to be seen which cell types are important in 
mediating these APOE isoform dependent effects on neurodegeneration, as APOE is largely produced in 
astrocytes and microglia but its expression is also induced in other cells in the CNS.  
 
Microglia may contribute to tau spreading through the brain.  One recent study reported that after tau 
virus injection into the entorhinal cortex, ablation of microglia reduced phosphorylated tau, reduced tau 
spread from entorhinal cortex to dentate gyrus, and lowered proinflammatory cytokine levels 51.  Other 
studies have increased microglial activity by blocking or genetically removing the fractalkine receptor, 
which is constitutively activated by neuronally-released fractalkine (CX3CL1) to suppress microglial 
activation. Genetic removal of CX3CL1 results in increased tau phosphorylation in wild type and hTau 
overexpressing mice, via microglia-derived soluble factors 52. In support of this, CX3CL1 overexpression in 
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the rTg4510 model, suppressed microglial activation and subsequent tau pathology 53. While interesting, 
there are caveats to these studies including small animal numbers and the possibility that reducing 
microgliosis likely reduced levels of inflammatory cytokines which in themselves could contribute to the 
spread of tauopathy.  Further work is necessary to understand the potential role of microglia and also 
astrocytes in the early spread of tau through neural circuits. 
 
[H2] Glial phenotypes change during ageing  
In addition to their effects on amyloid and tau pathology, glial changes may be important for other aspects 
of AD pathogenesis independent of the amyloid cascade. Age is the largest risk factor for AD, yet we do not 
fully understand why age renders the brain susceptible to neurodegeneration. A recent genome-wide 
analysis of microglia in mice showed distinct region-dependent transcriptional identities that changed with 
age 54. Similarly, analysis of astrocytes from different regions of mouse brain during ageing showed age-
associated and region specific transcriptional changes 55.  Interestingly these age-associated astrocyte 
changes were reduced in mice lacking microglial secreted cytokines, indicating important interactions 
between microglia and astrocytes during ageing 55.  In support of the translational relevance of these age-
associated changes observed in mice, we observe differences in the distribution of microglia and 
astrocytes in different brain regions in healthy aged human brain 56, suggesting that regional differences in 
ageing of glia could contribute to selective vulnerability in age-related neurodegenerative diseases like AD.  
In a recent mouse study profiling the translatome of microglia, ageing, APP/PS1 overexpression, and P301L 
tau overexpression all induced a similar network of translational changes strongly implicating APOE in 
driving a network of changes resulting in production of the cytokines CCL3 and CCL4 57.  The effects in this 
study were more pronounced in microglia from female mice.  While this is a single paper utilising AD 
animal models, it points to the intriguing idea that the AD risk factors of age, APOE isoform, and female sex 
may converge on similar inflammatory pathways that are induced by the pathological proteins that 
accumulate in the disease.   
 
[H2] Glial effects on neuron death 
Neurons begin to die early in AD pathogenesis.  By the time symptoms are detectable, estimates indicate 
that over half of neurons in layer II of the entorhinal cortex are lost 58.  Microglial phenotypes and their 
effects on neuron death have recently been shown to change with disease stage.  In a mouse model of 
neurodegeneration downstream of p25 overexpression, microglia appear to proliferate early, then later 
initiate a harmful host of innate immune responses 59.  Microglia also influence neuron death in a human 
cell tri-culture system in which neurons and astrocytes expressing mutant APP are cultured in a three-
dimensional chamber and microglia are added in a surrounding, connected chamber at later time points 60.  
In this system, infiltrating microglia contribute to neuron death in a pathway involving Toll Like Receptor 4 
and interferon-.  This has several limitations including overexpression of mutant APP and the use of an 
immortalized microglial cell line, but it does support a role for microglia in inducing death of human 
neurons 60,61.  While these results from model systems are intriguing, it will be important to examine other 
models and human brain to fully understand how microglia change with disease stage and which changes 
may contribute to neurodegeneration.  It will also be important moving forward to distinguish microglia 
from infiltrating microglia-like macrophages which enter the brain during disease and may have distinct 
roles compared to resident microglia 62-64.   
 
Astrocytes are also able to modulate neuron death via their expression of APOE.  In mice, APOE3 
expression in neurons or astrocytes and APOE4 expression only in astrocytes protected APOEnull mice 
from excitotoxicity, while neuronal expression of ApoE4 was not protective and led to neuron death after 
excitotoxic challenge 65. While excitotoxicity has not been established as the cause of cell death in AD, this 
study provides proof of principle that the cellular source of ApoE4 influences neuronal susceptibility to 
neurodegeneration, and indicates that glia may impact cell death independently of amyloid.   
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[H2] Cellular cross-talk in inflammation 
Along with their independent roles in neuroinflammation, there is increasing evidence for interactions 
between microglia and astrocytes in destructive feed-forward loops in AD. Work from Ben Barres’ group 
showed that secretion of cytokines by microglia can activate astrocytes causing them to lose some of their 
physiological functions and become toxic to neurons 66. In AD models, two studies showing that IL-10 
worsens amyloid-related phenotypes in mice also implicate microglial IL-10 in boosting astrocytic 
expression of APOE, which then looped back to decrease microglial appetite for Aβ 67,68.  The complement 
system also plays a role in microglia-astrocyte cross talk.  In a recent study examining both plaque bearing 
transgenic mice and cultured astrocytes and microglia, Aβ was found to activate astrocyte expression of 
NF-κB, which caused extracellular release of complement 3. This in turn caused microglial and neuronal 
C3a receptor activation, which impaired cognitive function and altered microglial Aβ phagocytosis 69.  
Immune system-related genes including clusterin and complement C3 are differentially expressed in laser-
captured astrocytes from human AD brain compared to control brains 70, further implicating an 
inflammatory immune response in multiple cell types in AD. 
 
Microglia and astrocytes both secrete cytokines in the AD brain. Treating cultured microglia with amyloid 
induces secretion of numerous proinflammatory mediators such as IL-1β, IL-6 and TNF-α, as well as 
reactive oxygen species 71.  All of these factors can be released in differing combinations depending upon 
the pathological context and have significant detrimental effects on the surrounding milieu. Importantly, 
some of these molecules can induce the activity of γ-secretase, leading to enhanced Aß production 72. 
Exposure of cultured astrocytes to oligomeric Aβ similarly induces astrocyte activation 73 and to the release 
of proinflammatory cytokines such as IL-1β and TNF-α and the gaseous synaptic modulator, nitric oxide 
(NO) 74. APOE genotype influences the inflammatory response of glia to Aß exposure.  APOE4 expression in 
a mouse model of AD with plaque deposition resulted in increased microglial and astrocytic reactivity and 
increased release of  inflammatory cytokines, particularly in plaque-associated microglia 75. TNF-α has 
received a lot of attention as TNF receptor-1-knockout mice have significantly lower levels of amyloid 
production and deposition in an AD mouse model 76.  In mouse models of familial AD that develop plaques 
and in wild-type animals injected with oligomeric Aβ, Aβ is associated with increasing levels of cytokines, 
confirming that Aβ induces cytokine release in vivo 77,78.  While much work focuses on pro-inflammatory 
cytokines, there is also evidence that the anti-inflammatory cytokine IL-10 worsens amyloid pathology and 
cognition in mouse models 67,68. Understanding the complex role of cytokines will be important, 
particularly since cytokines may contribute to neuron death 79. 
 
Complex cellular responses to systemic infection may also contribute to disease pathogenesis.  The 
controversial idea that pathogens contribute to the initiation of AD has been around for decades 80,81, but 
has received a recent boost from 2 papers examining herpes infection in human AD and in a mouse model 
of disease.  An extensive analysis of multiple human cohorts found higher levels of herpesvirus 6 and 7 in 
brain tissue from AD cases than controls, and computational analyses indicate that the viruses may 
regulate known Alzheimer’s genes 82.  The increase of virus in the brains of people with AD could plausibly 
be due to the known disruption of the blood brain barrier in disease, which allows these very common 
viruses to get into the brain.  More mechanistically convincing is the recent study, which showed that 
herpes simplex virus 1 infection leads quickly to amyloid deposition in an AD mouse model and a human 
stem cell derived neuronal culture model 83.  This builds on work indicating that Aβ has antimicrobial 
properties 84.  Whether this is important to AD pathogenesis remains controversial, particularly since 
plaque deposition is not sufficient to initiate full-blown Alzheimer’s disease 44.  However, it is possible that 
these processes may turn out to play a causative role in disease initiation, and there is no doubt that 
interactions of multiple cell types from the vasculature through glia and neurons are involved in this type 
of response to infection. 
 
[H2] White matter and oligodendrocytes 
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While there is substantial evidence supporting a role for microglia and astrocytes in AD pathogenesis, there 
has to date been less investigation of a potential role for oligodendrocytes or their precursor cells (OPCs).  
White matter changes, as observed by MRI scans,  are frequent in AD with recent studies showing 
associations of white matter damage with both amyloid 85 and tau pathology  86.  Intriguingly, 
neuropathological studies do not generally reflect substantial white matter changes, although post mortem 
evidence of volume changes would be difficult to observe.  
 
Early on, Braak observed that the pattern of neurofibrillary tangle deposition in AD parallels the 
developmental pattern of myelination 87, indicating that neurons with late-myelinating axons may be more 
vulnerable to degeneration, although the molecular link between these observations remains uncertain.  
Some gene variants that increase AD risk are predominantly expressed in oligodendrocytes or their precursor 
cells (table 1), and emerging evidence suggests that myelination is involved in neuronal plasticity 88, 
indicating that changes in these cells may contribute to the disease. Incubation of cultured oligodendrocytes 
with amyloid peptides, leads to apoptotic cell death 89 and injection of amyloid into the rat corpus callosum 
leads to axon damage, oligodendrocyte death and reactive gliosis around the injury 90. Inflammatory 
conditions such as those observed in AD can hinder the remyelination process, and prevent OPCs from 
differentiating to oligodendrocytes 91. Although not yet fully substantiated, these potential oligodendrocyte 
processes provide further support for the importance of interactions between cell types in disease. 
 
[H1] Cellular interactions in synapse loss 
For almost three decades it has been known that the strongest neuropathological correlate with cognitive 
decline in AD is synapse loss 92. Synapse loss occurs early in the disease and continues to parallel cognitive 
decline throughout disease progression 92-96. The exact mechanisms driving this loss are yet to be fully 
elucidated, although it is evident that both amyloid and tau exert harmful effects on synapse integrity 97. 
Strong focus has been placed on the neuronal components of the synapse as excitatory glutamatergic 
synapses have historically been considered dipartite structures, consisting of a presynaptic terminal and 
postsynaptic spine. However, detailed imaging studies have revealed that many exist as tri- or even quad-
partite structures with glial processes found in close proximity to the synapse. These non-neuronal synaptic 
components play important roles in synapse development, maturation and disease.  Prior to synapse loss in 
AD, amyloid and tau accumulate in the synapse leading to disrupted function of glutamate receptors and 
synaptic kinases, altered calcium dynamics and spine disassembly 98. These direct effects on the neuronal 
components of the synapse are well established and supported by a growing literature describing 
presynaptic, postsynaptic and trans-synaptic effects of these pathological factors 97. However, the disease-
driven disruption of glial function and their subsequent influence on synaptic physiology remain an area of 
intense research. 
 
[H2] Immune cascades and synapse loss in AD 
Over the past few years, data have emerged implicating both astrocytes and microglia in activity-dependent 
synaptic pruning during development 99-103.  The classical complement cascade has emerged as a key part of 
this developmental synaptic pruning 104-106. In the developing mouse brain, synapses expressing high levels 
of compliment components C3 and C1q are actively engulfed and phagocytosed by compliment receptor 3 
(CR3) positive microglia 100,104.  Recent data indicate interactions between astrocytes and microglia in 
developmental synaptic elimination as microglial secretion of inflammatory molecules including C1q induces 
astrocyte activation, which causes neurotoxicity, at least in cultured cells 66.  Conversely, astrocytes can 
recruit microglia to eliminate synapses. By releasing transforming growth factor β (TGF-β), astrocytes in the 
retina increase the expression of complement protein C1q on nearby synapses thus priming them for 
complement-dependent phagocytosis by recruited microglial cells 107. Intriguingly, the astrocytic elimination 
of synapses was also recently shown to be modified by APOE isoform. In young mice, ApoE2 increased 
astrocytic phagocytosis of synaptic terminals, whereas ApoE4 decreased astrocytic phagocytosis 108. 
Complement C1q was also low in APOE2 expressing mice and high in APOE4 mice, suggesting that ApoE4 
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may prevent astrocytes performing physiological C1q-dependent synapse clearance, leading to a build-up of 
senescent synapses 108.   
 
While much of the evidence for the involvement of the complement cascade in synapse elimination comes 
from studies of developing retinal ganglion cells in rodents, this cascade may also be involved in synapse 
degeneration in AD.  Several genes associated with the complement system have emerged as AD genetic 
susceptibility factors, including compliment receptor 1 (CR1) and clusterin 109. Furthermore, many 
components of the compliment cascade are significantly up-regulated in the AD brain 110. Evidence from 
mouse models suggests that amyloid-induced complement activation leads to microglial phagocytosis of 
cortical synapses 111,112. In mice, soluble amyloid drives the up-regulation in C1q levels before the deposition 
of amyloid in plaques and, C1q knock-out significantly reduced the synaptotoxic effect of amyloid 111. Genetic 
removal of complement C3 from APP/PS1 mice (APP/PS1;C3-KO) rescued synapse loss in the hippocampus, 
and knocking out CR3 (the receptor for C3) resulted in less synaptic engulfment by microglia following 
amyloid challenge 111. APP/PS1;C3-KO mice have revealed some clues as to the roles of glia in amyloid 
clearance. In 16 month old APP/PS1;C3-KO mice, plaque burden was increased compared to APP/PS1, 
however they showed an altered glial response to amyloid plaques, namely decreased glial infiltration of 
plaques and lower levels of proinflammatory cytokines such as TNF-α and IFN-γ  112. This associated with 
partial preservation of synapse density in the hippocampus and improved cognitive flexibility, suggesting 
that C3-mediated synapse loss is a feature in aged and AD brain 112.  The idea that microglia are 
phagocytosing synapses in the human AD brain remains controversial.  Even in rodent slice culture, there is 
some debate about whether microglia actively eat postsynaptic dendritic spines with one study proposing a 
role for microglia in synaptic circuit remodelling by “nibbling” presynaptic terminals and facilitating 
postsynaptic filopodia formation 113.  On balance the human genetic data and mouse model data strongly 
support a role for complement and microglia in synapse degeneration, but the details of this remain to be 
determined, particularly what is happening in human AD brain. 
 
Immunological systems and cytokines beyond the complement system also contribute to synapse 
degeneration in AD. For example, the major histocompatibility complex 1 (MHC1) immune pathway has been 
shown to influence synapse function and formation 114. MHC1 associates with PSD-95 and can interact with 
a number of immunoreceptors, including paired immunoglobulin-like receptor B (PirB) 114. Neuronal PirB 
associates with synapses and plays a critical role in ocular dominance plasticity (ODP). When PirB is knocked 
out, ODP is enhanced 115 however in APP/PS1 models of AD, defective ODP is a very early marker of synaptic 
dysfunction 116. It has since been discovered that PirB acts as a receptor for amyloid oligomers and this 
interaction induces synaptic dysfunction and synapse loss by disrupting the synaptic cytoskeleton 117. 
Removal of PirB could rescue synaptic plasticity deficits and behavioural changes in AD mice 117. Importantly, 
amyloid oligomers have a nanomolar affinity for the human orthologue of PirB, leukocyte immunoglobulin-
like receptor B2 (LilrB2) and although LilrB2 levels are not altered in AD brain, downstream signalling 
pathways are significantly upregulated 117. This suggests that in human AD brain, amyloid activates LilrB2 
and increases its downstream signalling, leading to altered neuronal actin organisation and ultimately 
synapse loss.  Further support of a microglial role in Aß-mediated synapse loss comes from a study of the 
APP/PS1 mouse model with knockout of TDP-43 in microglia.  TDP-43-KO increased microglial phagocytic 
activity and led to enhanced amyloid clearance and concomitant exacerbated synapse loss 118. This provides 
an intriguing link between the pathological proteins involved in AD and Amyotrophic Lateral Sclerosis (ALS), 
which also exhibits synapse loss associated with cognitive decline 119. 
  
[H2] Excitotoxicity  
In addition to the potential involvement in innate immune cascades, astrocytic end-feet at synapses are 
likely to play a role in synaptic dysfunction and loss in early AD, through modulation of excitotoxicity.  
Adenosine 2A receptors (A2ARs) are expressed on astrocytes and respond to synaptic adenosine by inducing 
a number of cellular changes, including a reduction in glutamate uptake 120. Astrocytic A2ARs have a negative 
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role in learning and memory processes in mouse models of AD and high levels of these receptors are found 
on human astrocytes in AD 121. Therefore, excitotoxicity in AD may be driven by increased astrocytic A2AR 
expression on astrocytes, leading to decreased glutamate clearance and excessive synaptic activity. 
Alternatively, genetically lowering glutamate transporter-1 (GLT-1) expression in AD mice, results in an 
earlier onset of cognitive deficits 122 and amyloid is known to increase the lifetime of synaptic glutamate by 
inducing the internalisation of GLT-1 from astrocytic membranes 123. Furthermore, restoring GLT-1 
expression in an AD mouse model prevented synaptic pathology and cognitive decline 124. Therefore, 
amyloid-induced alterations in GLT-1 location and function may increase synaptic and extrasynaptic 
glutamate, thus driving excitotoxicity in AD. In support of this, it is believed the beneficial role of Memantine 
in patients with moderate-to-severe dementia may be due to the blockade of extrasynaptic NMDA 
receptors, which are activated by excess glutamate 125.  
 
[H2] Risk genes influence synapse loss 
Astrocytes are also likely to influence synapse dysfunction and loss due to their production of ApoE and its 
effects on synaptic Aß 126.  We demonstrated a role for ApoE4 protein in targeting oligomeric Aß to synapses, 
where it is associated with synapse degeneration in human AD brain127. In mouse models, it is clear that the 
synaptic effects of ApoE4 are not cell-autonomous, as we observed that bathing the cortex in ApoE4 
expressed by viral infection of ependymal cells worsens synaptic phenotypes38. ApoE modulates Aß 
metabolism and clearance128,129, and ApoE4 increases the oligomerization of Aß130, which is toxic to 
synapses131,132.   Interestingly, the ApoE4 effect is not just a feature of neurodegenerative disease but also 
plays a role in synaptic integrity in non-pathological cognitive ageing. ApoE plays a role in dendritic spine 
maintenance 133, presynaptic terminal composition and glutamate synthesis 134 and synaptic plasticity 135, 
with ApoE-ε4 isoforms having significant detrimental effects in these studies. A recent study utilising 
transgenic mice that express human ApoE isoforms, discovered an isoform-specific change in the phagocytic 
properties of astrocytes 108.  Non-demented individuals from the Lothian Birth Cohort in their 9th decade of 
life exhibit a faster rate of cognitive decline if APOE4 positive, compared to those with APOE2 or APOE3 
alleles 136.  Future work on the well-characterized Lothian Birth Cohort subjects will help to clarify the role 
of factors such as APOE in cognitive ageing through deep phenotyping of genetic, psychosocial, and 
neuropathological factors 56,137,138. 
 
In addition to the clear links between Aß, glia, and synapse loss, there are indications that tau mediated 
synapse loss also involves glia. Early studies in the P301S mouse model of tauopathy revealed that microglial 
activation coincided with the onset of synapse loss 139. This occurred before neuron loss and tau tangle 
formation, placing active microglia at the right place and time to induce synaptic alteration 139. The effects 
of TREM2 modulation of tau-induced synapse degeneration have not yet been fully explored, but one study 
showed that overexpressing TREM2 in microglia in these mice improves cognition and prevents loss of 
synaptic proteins 49. There are also hints that astrocytes modulate synapse degeneration in tau mice. 
Cultured astrocytes from the P301S tauopathy model exhibit functional deficiencies that result in a failure 
to support neurons in culture 140.  GLT-1 is decreased in P301L mice indicating that astrocytic clearance of 
glutamate is impaired by tau expression in this model 141, which may contribute to excitotoxicity. 
Extracellular tau oligomers also disrupt astrocytic Ca2+ signalling, reduce astrocytic ATP release, and impair 
neuronal synaptic function in culture 142. 
 
Together, these data strongly support the notion that multiple cell types contribute to synaptic changes 
(figure 1).  This opens promising avenues to prevent or reverse synapse degeneration and potentially to 
prevent the spread of pathological proteins through neural circuits. 
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Figure 1:  Synapse loss occurs early in AD pathogenesis. Emerging data indicate that microglia, astrocytes, and cross-
talk between these are involved in synapse degeneration. Ageing, early pathological changes in Aß and tau, 
and chronic hypoperfusion due to vascular impairments all contribute to synapse loss directly and indirectly 
via effects on microglia and astrocytes.  Microglia and astrocytes also have direct effects on synapse 
degeneration and there is cross-talk between the glial pathways impacting synapses. 
 
 
[H1] Role of the NVU in neurodegeneration  
The brain is an energy hungry organ, dependent upon blood vessels for delivering oxygen and nutrients and 
for waste removal.  An intricate control system has evolved to both protect the brain from components in 
the blood that are toxic to brain cells (the blood-brain barrier, BBB) and to regulate blood flow to different 
brain regions with fluctuating energy demands. This Neurovascular Unit (NVU) contains almost every cell 
type found in the brain, all working together in a tightly regulated manner.  Vascular cells (endothelial cells, 
pericytes, and vascular smooth muscle cells) form the walls of the vessels.  These are surrounded by 
astrocyte end feet, the terminal processes of astrocytes.  Perivascular microglia and macrophages survey the 
influx of blood-borne molecules into the brain 143.  The different cell types in the NVU communicate and are 
interdependent.  For example, endothelial cells can promote proliferation and differentiation of both neural 
precursors and oligodendrocyte precursor cells 144,145, and via the release of trophic factors, also protect 
neurons from injury 146. 
 
Strong epidemiologic evidence shows associations between vascular risk factors and risk for AD, and 
further that mid-life statin use to control high blood pressure is protective against AD 147.  Recent studies 
show reductions in incidence of AD in the UK 148, and while the causes for this remain unknown, scientists 
speculate that better access to healthcare and lowered cardiovascular risk factors may be contributing to 
reduced incidence. Disruptions in NVU certainly cause vascular dementia 7 and likely also contribute to the 
early stages of AD pathogenesis. It has been proposed that damage to the NVU starts a cascade involving 
reduced cerebral blood flow and BBB disruption, which when followed by a “second hit” of Aß pathology 
leads to Alzheimer’s disease 8.  In animal models, vascular changes have been observed very early in the 
disease process. Reductions in cerebral blood flow and vascular reactivity are the first changes observed in 
a model overexpressing Swedish mutant APP 149,150 and APP/PS1 mice exhibit ultrastructural changes in 
microvasculature before cognitive impairment is observed 151.  Tau overexpressing mice also develop 
vascular abnormalities, even those expressing wild-type human tau, which do not develop overt 
neurodegenerative phenotypes 152. In humans, using dynamic contrast enhanced magnetic resonance 
imaging (MRI), decreases in hippocampal vascular volume have been observed in mild cognitive 
impairment (MCI) subjects 153, and increased BBB permeability has been observed even at an early stage of 
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AD 154.  Brain glucose uptake measured by [18F]fluoro-2-deoxyglucose PET imaging is impaired in AD 
patients very early in the disease process 155.  While these imaging studies have relatively small sample 
sizes (6-15 subjects per group), they do point to a link between vascular damage and AD.  Large biomarker 
studies also point to the role of vascular malfunction as an early event in AD.  In the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) cohort, a data-driven model spanning 30 years of disease progression 
suggests that vascular dysregulation is one of the earliest events in Alzheimer’s disease 156. 
 
Along with direct effects of oligodenrocytes on myelin integrity discussed earlier, vascular changes can also 
impact white matter.  White matter hyperintensities detected by T2-weighted MRI have emerged as an 
important biomarker of white matter damage.  While the pathological causes and consequences of these 
hyperintensities remain to be fully determined, they have been associated with small vessel disease, glial 
cell death, microglial and endothelial cell activation, demyelination, axonal loss, and tau pathology in 
overlying cortex, linking many aspects of the NVU 86,157,158.  A well-powered imaging study from the 
Dominantly inherited Alzheimer Network (DIAN) found white matter hyperintensities in people with familial 
AD mutations that began 6-22 years before symptom onset 159. 
 
There are some hints at mechanisms linking vascular changes to AD, with the strongest evidence favouring 
defective clearance of A from the brain to the periphery and chronic hypoperfusion as two of the 
contributors to sporadic AD.  The routes of clearance of A from the interstitial fluid, and indeed the routes 
of brain extracellular fluid drainage in general is not entirely clear and has been hotly debated over the 
past decades 160. While A can be degraded in the parenchyma, a large part of A clearance from the brain 
appears to be via the vasculature drainage, driven at least in part by para-arterial influx of cerebrospinal 
fluid (CSF) that causes convective fluid flux forcing interstitial fluid (ISF) out through para-venous efflux 
(known as the glymphatic system) 10,161-164. Meningeal lymphatics have also been recently implicated in A 
clearance in rodents 165.  In this study, impairment of lymphatic drainage impacted glymphatic exchange of 
CSF and ISF 165, implying that lymphatic and glymphatic drainage processes may be functionally linked – 
perhaps via effects on glia. Intriguingly, both production and clearance of A change with the sleep-wake 
cycle with higher levels of A in CSF and ISF reported during periods of more brain activity in mice and 
humans 166,167.  This is doubtless due in part to the increased secretion of A with increasing neuronal 
activity 168, but astrocytes are most likely involved in this process as well since glymphatic clearance is 
enhanced during sleep 169. Several genetic risk factors for AD including APOE, clusterin, and PICALM have 
been implicated in vascular clearance of A 170-172.  Polymorphisms in aquaporin-4 are associated with 
modulation of cognitive decline in AD 173, which could be important because of the role of aquaporin-4 in 
the influx of CSF into the brain as part of the glymphatic system 164.  Similarly, inducing pericyte loss in APP 
overexpressing mice by knocking down pericyte-deficient platelet-derived growth factor receptor- 
resulted in exacerbated amyloid pathology. Pericyte loss also caused accumulation of tau pathology and 
neurodegeneration 174. However, the role of pericytes in regulating cerebral blood flow and protein 
clearance from the brain remains controversial 175.  
 
The role of the NVU in AD goes beyond protein clearance.  Hypoperfusion, hypoxia, and breakdown of the 
BBB are all thought to contribute to pathogenesis, processes which all involve complex interactions of 
multiple cell types 8.  For example, in mouse models of early AD, hypertension enhances A induced NVU 
dysfunction and promotes BACE activity and subsequent A production 176. Tau pathology has also recently 
been linked to changes in brain microvasculature.  Mice overexpressing human wild-type tau or FTD 
associated mutant tau both develop changes to blood vessel structure which are associated with 
obstructed blood flow 11. These data indicate that changes in neuronal expression of tau impact 
endothelial cell biology, further supporting an important role for cell-cell interactions in AD.  
 
As observed in parenchymal inflammation, perivascular microglia likely play a protective role early in the 
disease process by phagocytosing Aß and potentially also phagocytosing extracellular tau as it propagates 
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from cell to cell.  In support of this idea, in Tg2576 mice, decreased microglial perivascular accumulation 
correlated with increased deposition of cerebral amyloid angiopathy (CAA) and decreased survival of 
remaining microglia, which developed a pro-inflammatory phenotype and impaired the BBB 177.  
 
Hypoperfusion due to vascular changes and neurotoxic changes including glial activation both lead 
oxidative stress through generation of reactive oxygen species (ROS), which can contribute to a negative 
spiral of degeneration. Accumulation of ROS can result from excessive production due to increased activity 
of superoxide-producing enzymes such as NADPH oxidase, or inhibited function of anti-oxidant enzymes 
such as superoxide dismutase (SOD) 178. This fine balance of pro- and anti-oxidant activity is particularly 
vulnerable in the brain due to its high abundance of polyunsaturated fatty acids, high metabolic rate and 
relatively low expression of antioxidant molecules 179. However, given the devastation observed in the 
human AD brain it is no surprise that oxidative stress is evident, the important question is whether 
oxidative stress is a cause of AD pathogenesis, or is a result of it. Animal models suggest that oxidative 
stress occurs before or in tandem with amyloid plaque formation 180,181 and human studies suggest that 
oxidative stress represents an early pathological event in Alzheimer’s disease 182. Oxidative stress can 
result in neuronal death; however ROS can also have detrimental effects on other cell types in the brain. 
 
Cerebral amyloid angiopathy (CAA), the build-up of amyloid on cerebral vasculature, can lead to vascular 
oxidative stress, via the generation of ROS, and this exacerbates vascular dysfunction. Animal models suggest 
that NADPH oxidase is the major source of toxic free radicals, as genetic removal of Nox2 (a catalytic subunit 
of NADPH oxidase) counteracts amyloid-induced, ROS-dependent, vascular dysfunction 183. Furthermore, 
vascular endothelial cells and perivascular microglia/macrophages express the amyloid-binding receptor 
CD36 184. This receptor increases CAA and is important in the amyloid-induced oxidative stress within the 
neurovascular unit 184. Interestingly, genetic removal of this receptor results in reduced CAA, reduced 
vascular dysfunction and improved cognitive function in Tg2576 mice, despite no change in cortical amyloid 
plaque burden 184. More recent animal work has suggested the source of amyloid-dependent oxidative stress 
is CD36-positive perivascular macrophages185. Depleting perivascular macrophages in Tg2576 mice with 
clodronate, led to decreased amyloid-dependent vascular dysfunction and this was dependent on CD36 and 
Nox2 expression 185. This confluence of reactive oxygen species, loss of bioenergetics, and inflammatory 
responses involving the neurovascular junction, as well as organ level clearance mechanisms together may 
lead to an imbalance in Aß homeostasis or in tau spreading mechanisms that help “tip the balance” towards 
progression of disease. 
 
 
[H1] Therapeutic implications  
Much of the clinical trial landscape for the past 20 years has been dominated by the amyloid cascade 
hypothesis on the assumption that lowering Aß levels will protect neurons.  While confidence in the 
validity of the amyloid cascade remains high, all trials targeting Aß to date have failed to improve 
cognition, and it is now considered possible that anti-Aß interventions will need to be carried out at very 
early stages of the disease, long before symptoms begin, to prevent neural system failure and cognitive 
impairments.  These clinical failures and the emerging evidence of the importance of cellular interactions 
that impact AD have led to a broadening view of therapeutic targets that may prevent or reverse 
pathological changes in non-neuronal cell types. 
 
Activation of microglia and astrocytes and the downstream effects on neurons are likely important players 
early in disease pathogenesis, which offer potential therapeutic targets. Increasing ApoE secretion by 
astrocytes could be beneficial due to enhancing clearance of Aß and potentially enhancing synaptic 
function 186. Bexarotene, a drug in clinical use to treat skin cancer, has generated interest due to its ability 
to aid the formation of ApoE lipoprotein particles.  A study published in 2012 indicated that bexarotene 
treatment increased brain ApoE concentrations, reduced Aß levels, and reversed cognitive deficits in 
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APP/PS1 mice 187. This led quickly to clinical trials, however subsequent mouse work has failed to replicate 
the full benefits seen in the original study 188-190. The initial outcomes from clinical trials have similarly not 
shown much benefit, only lowering brain Aß levels in people who do not have an APOE4 allele and 
increasing serum triglycerides which could increase cardiovascular risk 191.  Despite these lukewarm results 
with bexarotene, there is promise in the idea of harnessing APOE levels as a therapeutic, and it may be 
that lowering ApoE levels will be more helpful as a preventative strategy than raising them. Mouse work 
indicates that increasing levels of ApoE2, lowering levels of ApoE4, or lowering total ApoE levels in the 
brain may be beneficial to reduce amyloid levels, enhance synaptic function, and prevent tau mediated 
toxicity 38,50,192. 
 
Another potential therapeutic target based on cellular interactions in AD is inflammation. A large 
prospective study found that use of non-steroidal anti inflammatory drugs (NSAIDs) is associated with 
lowered risk of AD 193. However, thus far, anti-inflammatory drugs have failed in clinical trials for AD 
despite protecting against many phenotypes in mouse models 194.  Human data indicate that anti-
inflammatory treatment effects differ at different stages of disease 195, consistent with our conclusion that 
the role of glia likely changes during the disease course. Although it is still in very early stages, the 
development of C1q antibodies to treat AD will be of interest based on the involvement of the 
complement system in synapse loss 196. 
 
At the interface of vascular risk factors and inflammation, diabetes drugs have gained interest as potential 
therapeutics for AD  197.  Promising mouse work indicates that hyperinsulinemia exacerbates AD pathology 
and that anti-diabetic drugs improve phenotypes in AD models 198,199.  However, clinical trials with two 
agonists of the peroxisome proliferator-activated receptor-gamma (PPAR), diabetes drugs used to control 
blood sugar, did not succeed in either symptomatic or prevention trials 200 (press release 
https://www.takeda.com/newsroom/newsreleases/2018/takeda-tommorrow-trial/ ). 
 
Despite disappointing clinical trial results, it is not clear whether therapeutics aimed at APOE, anti-
inflammatories, or lowering insulin levels have been adequately studied in humans to date.  
 
Along with therapeutics that target non-neuronal cells, preventative strategies that address the entire 
NVGU are a promising approach.  Recent population based studies indicate that the incidence of dementia 
in many countries is stable or decreasing 201.  While the reasons for this are not known, it is likely that 
improved cardiovascular health - through initiatives like reducing smoking  - is a contributing factor.  
Epidemiological studies show an association between exercise and reduced risk of cognitive decline and 
dementia during ageing 6,202.  However, to date, interventional trials to prevent or treat dementia by 
improving cardiovascular health via exercise have inconsistent results trending towards no benefit 203,204. 
 
 
[H1] Concluding Remarks 
Healthy brain function relies on intact neural system integrity, which encompasses the intricately 
choreographed workings of multiple cell types.  Here we have outlined that in AD there are changes in 
multiple cell types and the interactions between them (figure 2).  Strong data from genetic and 
epidemiologic risk factors implicate vascular and glial changes in initiating AD.  A disease that plays out 
over more than a decade, however, might be expected to have multiple moving parts; the role of glia or 
vasculature abnormalities in each portion of this cascade may change over time, and are also likely to 
change in the context of aging and other systemic and environmental factors.  While it is tempting to try to 
arrange “cause and effect” arrows in cartoon models of hypotheses, it thus seems very likely that the 
complexities involved will be difficult to conclusively model in simple systems; we believe that further 
evaluation of deeply phenotyped human material from patients at different stages of the disease, and with 
different genetic risk factors and predispostions, will be critical to advance understanding. Nonetheless, 
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increasing evidence from cell and animal studies implicates the interactions between cell types in 
damaging synapses and neural circuits, and emphasizes the need for further studies. There is hope that 
with a clearer understanding of the interactions between cells in the brain and the time course of the 
changes, we will be able to either prevent or treat AD. 
 
 
Figure 2: Schematic of the NVU and early changes in Alzheimer’s disease.  All of the cell types in the brain interact in 
a complex web to maintain brain function (left). During the early stages of Alzheimer’s disease (right), many 
of these homeostatic processes are impaired, and synapses and neurons are damaged by pathways involving 
multiple cell types.  Vascular integrity (1) is impaired by damage to endothelial cells, astrocytic endfeet, and 
pericytes and and by the build-up of Aß along vessel walls in cerebral amyloid angiopathy. These vascular 
changes cause impairments in vascular clearance of proteins, hypoperfusion, breakdown of the blood brain 
barrier (BBB).  Amyloid plaques (2) are surrounded by a halo of oligomeric Aß which damages nearby 
synapses and neuronal processes. Plaques are also surrounded by astrocytes and microglia which intially 
serve to clear amyloid protein but after exposure to Aß become reactive and secrete cytokines.  Tau 
accumulates in neurofibrillary tangles within neurons (3) which are associated with glial accumulation and 
neuronal dysfunction and death. Synapses become dysfunctional and disappear (4) in a process that likely 
involves microglia.  White matter integrity is compromised (5) due to loss of oligodendrocytes and damage 
to myelin caused by chronic hypoperfusion. 
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Box 1: Alzheimer’s pathology –neurons and beyond  
Degenerative changes in the brains of AD patients include the accumulation of “positive” lesions such as amyloid 
plaques, neurofibrillary tangles, neuropil threads, dystrophic neurites, cerebral amyloid angiopathy, and glial 
Nature Reviews Neuroscience Manuscript – Henstridge, Hyman, and Spires-Jones 
 
25 
responses as well as the “negative” lesions of synapse and neuronal loss 205 206 207.  Plaques are extracellular 
deposits of the amyloid beta (Aß) peptide, which is generated from the sequential cleavage of the amyloid 
precursor protein by  and -secretase enzymes 208,209.  Plaque deposition begins in the neocortex years 
before symptom onset, then progressively spreads to hippocampus, diencephalon and striatum, brainstem, 
and lastly cerebellum 210.  Soluble oligomeric forms of Aß rather than plaque fibrils, are toxic to neurons and 
synapses, but the exact forms of the toxic oligomers and how they confer toxicity remain hotly debated 211. 
 
Neurofibrillary tangles are intracellular lesions composed of misfolded, hyperphosphorylated tau protein 212,213. 
Tangle accumulation occurs early in the transentorhinal cortex then spreads to the entorhinal cortex, 
hippocampal formation, and later to neocortex 214,215.  Unlike plaque accumulation, the presence of tangles 
correlates with neuron loss, synapse loss, and cognitive decline 216,217.  Like amyloid, it is likely that soluble 
forms of tau are toxic, but the precise toxic forms remain unknown 218,219. 
 
Drastic brain atrophy occurs in AD particularly in medial temporal lobes and later in frontal lobes 205.  This 
progressive atrophy can be observed longitudinally in vivo with structural MRI, 219 which is increasingly used 
as a biomarker of disease progression. 
 
Reactive astrocytes (labelled with GFAP in top of figure) and activated microglia (labelled with Iba1, in bottom of 
figure) accumulate around plaques (arrowheads) and in the vicinity of tangles (arrows) 45,205 Figure 
reproduced with permission. 
 
 
 
 
 
Figure legends 
 
 
Table 1: Changes in multiple cell types in the brain early in Alzheimer’s disease.This table highlights the normal 
functions of several brain cell types and how these change in early Alzheimer’s disease pathogenesis. 
Cell Type Normal function  Changes in Early AD references 
microglia • Trophic support • Microgliosis 13,220,221 
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• Brain 
surveillance 
• Phagocytosis of 
debris 
• Beneficial and impaired clearance 
of amyloid and tau 
• Release of neurotoxic and 
proinflammatory factors 
• Excessive synaptic phagocytosis 
astrocyte • Trophic support 
• Metabolic 
support 
• Blood-brain-
barrier 
component 
• Synaptic 
modulation 
• Astrogliosis 
• Beneficial and impaired clearance 
of amyloid and tau 
• Release of neurotoxic and 
proinflammatory factors 
• Synaptic phagocytosis 
• Impaired synaptic homeostasis 
• BBB breakdown 
 
221-223 
oligodendrocyte • Trophic support 
• Myelin 
production 
• Loss of oligodendrocytes  
• Myelin loss 
• Disrupted neuronal plasticity 
224,225 
neuron • Electrical and 
chemical 
transmission 
• Excitatory and 
inhibitory 
synaptic activity 
• Synaptic 
plasticity, circuit 
function, 
cognition 
• Intracellular tau aggregation 
• Synaptic accumulation of amyloid 
and/or tau 
• Synaptic dysfunction 
• Synapse loss 
 
2,97,226 
Cerebral Vascular cells 
• Endothelial 
cells 
• Pericytes and 
smooth muscle 
cells 
• Perivascular 
macrophages 
• Endothelial 
cells, pericytes, 
and astocytic 
end feet are 
essential 
components of 
BBB 
• Smooth muscle 
cells control 
blood flow 
• Perivascular 
macrophages 
aid clearance of 
toxins  
 
• Impaired amyloid clearance  
• Cerebral Amyloid Angiopathy  
• BBB breakdown 
• Obstructed blood flow 
• Decreased CNS glucose uptake 
• Oxidative stress 
 
2,10,162 
 
 
Table 2 
 
Risk allele Cell type(s)  gene function(s) references 
APOE4 Astrocytes, microglia Lipid metabolism  9 
ABCA7 All cell types Lipid metabolism  227,228 
CLU Astrocytes, OPCs Lipid metabolism, endocytosis 109,227,229 
SORL1 Astrocytes  Lipid metabolism, endocytosis  227 
TREM2 microglia Immune response 230-232 
PLCG2 Microglia Immune response 232 
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ABI3 microglia Immune response 232 
CR1 microglia Immune response 109,227 
CD33 microglia Immune response 227,228 
INPP5D microglia Immune response 227 
Bin1 Microglia, oligodendrocytes, 
neurons 
endocytosis 227 
PICALM Microglia/endothelial endocytosis 227,229 
ZCWPW1 OPCs, oligodendrocytes, 
microglia 
Epigenetic regulation 227 
NME8 All cell types cytoskeleton 227 
EPHA1 oligodendrocytes Ephrin receptor 227,228 
HLA-DRB5-HLA-
DRB1 
microglia, macrophages Immune response 227 
Table 1: Genetic risk factors for sporadic AD and the brain cell types where they are most highly expressed (for 
reviews with more exhaustive lists of risk genes, and database where we searched for cell types that express 
genes see 233-235). 
 
 
Glossary 
 Amyloid cascade hypothesis: Initially proposed in 1992, this hypothesis posits that the accumulation 
of amyloid beta (Aβ) is the initiating factor in Alzheimer’s disease pathogenesis, leading to the 
formation of amyloid plaques, neurofibrillary tangles, neuron loss and clinical dementia. 
 
Innate immune system: Reactive response that utilises chemical mediators to fight infection and 
clear foreign substances from the body by recruiting specialised immune cells. It can also activate a 
second wave of adaptive immune response by presenting antigens to adaptive immune cells. 
 
Secretome: All secretable factors released from a cell. 
 
Homeostatic gene: Gene encoding a protein involved in a homeostatic mechanism within the cell 
Cytokine: Small releasable signalling proteins that often have immunomodulatory effects. These 
include chemokines, interleukins and interferons and they can be released by numerous immune cell 
types, endothelial cells and fibroblasts. 
 
Oligomeric Aβ: Single molecules of amyloid beta (Aβ) are known as monomers. These monomers 
can aggregate to form oligomeric structures of 2 or more monomers, which can then accumulate 
into larger fibrillar forms of Aβ and deposit as the hallmark amyloid plaques. 
 
Glymphatic system: Drainage pathway found in the vertebrate central nervous system, which allows 
cerebrospinal fluid (CSF) to enter the brain alongside penetrating arteries and facilitates the removal 
of interstitial fluid (ISF) and waste products from the brain. 
 
